首页> 外文OA文献 >Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

【2h】

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

机译：Paliperidone Palmitate 3月在拉丁美洲精神分裂症患者中的疗效和安全性：来自两阶段3种随机，双盲研究的数据的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Adam J. Savitz; Haiyan Xu; Srihari Gopal; Isaac Nuamah; Maju Mathews; Bernardo Soares;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies [J] . Savitz Adam J., Xu Haiyan, Gopal Srihari, Revista Brasileira de Psiquiatria . 2019,第6期

机译：帕潘立酮棕榈酸酯3个月制剂对拉丁美洲精神分裂症患者的疗效和安全性：来自两项大型3期随机，双盲大型研究的数据的亚组分析
2. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study [J] . Adam J Savitz, Haiyan Xu, Srihari Gopal, Neuropsychiatric Disease and Treatment . 2017,第1期

机译：东亚精神分裂症患者帕潘立酮棕榈酸酯三个月一次的疗效和安全性：一项整体，随机，双盲，III期，非劣效性研究的亚组分析
3. PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study [J] . The international journal of neuropsychopharmacology . 2016,第Suppla1期

机译：PM419。帕潘立酮棕榈酸酯在亚洲精神分裂症患者中每月3个月对1个月的疗效和安全性：一项随机，双盲，非劣效性研究的亚组分析
4. A Phase I, Double-Blind, Randomized, Dose Escalating Crossover Study ofan Oral Formulation of Human Growth Hormone in Healthy Male Volunteers [C] . Steven M. Dinh, Puchun Liu, Ehud Arbit, Controlled Release Society annual meeting . 2004

机译：健康男性志愿者中人类生长激素口服制剂的I期，双盲，随机，剂量递增交叉研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized double-blind studies [O] . Adam J. Savitz, Haiyan Xu, Srihari Gopal, 2019

机译：帕潘立酮棕榈酸酯3个月制剂对拉丁美洲精神分裂症患者的疗效和安全性：来自两项大型3期随机双盲研究的数据的亚组分析
7. PMH27 Health resource use and cost analysis of Schizophrenia patients participating in a Randomized, Multicenter, Double-Blind, relapse prevention study of paliperidone palmitate 3-month formulation [O] . Benson C., Chirila C., Graham J., 2015

机译：PMH27参与帕潘立酮棕榈酸酯3个月制剂随机，多中心，双盲，复发预防研究的精神分裂症患者的健康资源使用和费用分析

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

著录项

引文网络

相似文献

相关主题

期刊订阅